Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Pharma
Teva agrees with Axsome to keep generic off market until 2038
The settlement will keep Teva's generic version of Axsome's major depressive disorder drug Auvelity off the market until at least 2038.
Kevin Dunleavy
Feb 10, 2025 11:28am
How J&J CEO broke a stalemate and won Intra-Cellular in M&A push
Feb 7, 2025 11:24am
FDA signs off on Johnson & Johnson's Spravato as a monotherapy
Jan 21, 2025 3:23pm
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
Intra-Cellular closing in on major depression nod for Caplyta
Jun 18, 2024 11:40am
